SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : UTHR-a Promising Biotech in the works here? -- Ignore unavailable to you. Want to Upgrade?

To: kendall harmon who wrote (10)8/22/1999 12:48:00 PM
From: LzzrdKing  Read Replies (3) | Respond to of 66
 
imo this is a major plus for UTHR, from alex brown report

<<Importantly, United Therapeutics has retained the lion's share of
commercial rights to both of its lead products. Hence, we believe that the
Company's earnings leverage could be very substantial.>>



To: kendall harmon who wrote (10)8/26/1999 7:22:00 AM
From: kendall harmon  Respond to of 66
 
Martine Rothblatt is the correct name of the founder, and I apologize for the inadvertent misspelling. The head of investor relations is Therese Fergo, not Fargo as earlier posted. Please make a note of it.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News